“You have systemic sclerosis,” says the physician.
Explore this issueAugust 2018
Also by this Author
Other somber words patients may hear the day they learn their diagnosis include, “rare, chronic, no treatment.” But a ray of hope could soon enter those exam rooms thanks to research conducted by a team from the UK.
Rizgar A. Mageed, PhD, FRCP, FRCPath, is professor of experimental immunology at the Centre for Experimental Medicine and Rheumatology at Queen Mary University of London. His most recent study, “Association of Defective Regulation of Autoreactive Interleukin-6-Producing Transitional B Lymphocytes with Disease in Patients with Systemic Sclerosis,” appears in the March 2018 edition of Arthritis & Rheumatology.1